Accera announces plans to launch Axona Alzheimer’s treatment

BROOMFIELD, Colo. Biotechnology company Accera plans to launch its Alzheimer’s disease treatment Axona this quarter, the company has announced.

Axona is a first-in-class medical food product for the dietary management of metabolic processes associated with mild-to-moderate Alzheimer’s. Clinical trials have shown it to safely improve cognitive function and memory in patients with the disease, the company said.

“The recent financing will allow us to launch Axona, a new and novel approach to managing Alzheimer’s disease,” Accera CEO Steve Orndorff said in a statement. “We have developed an experienced commercial manufacturing, sales and marketing team that has a history of successful commercialization of numerous CNS drugs.”